Treosulfan - Medac

Drug Profile

Treosulfan - Medac

Alternative Names: CB 2562; CB 40067; CCRIS 2781; Dihydroxybusulphan; HSDB 6963; NSC 39069; Ovastat

Latest Information Update: 05 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medac
  • Developer Center for International Blood and Marrow Transplant Research; Medac
  • Class Antineoplastics; Butylene glycols; Mesylates; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2017 Medac completes a phase III trial in Acute myeloid leukaemia and Myelodysplastic syndromes in Germany, Finland, France, Hungary, Italy and Poland (NCT00822393)
  • 28 Jul 2017 Treosulfan is still in phase II trials for Haemoglobinopathies, Immunodeficiency disorders, and Inborn error metabolic disorders (In adolescents, In children, In infants) in Poland, Italy, Czech Republic, Austria and Germany (IV) (NCT02349906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top